GHK-Cu: what the evidence says

The evidence

A small copper-binding peptide (glycyl-histidyl-lysine), first described in human blood (serum) in 1973.

Today it appears mainly in topical cosmetics. Injectable GHK-Cu is not an approved medicine, and the US FDA has flagged potential safety risks of compounded injectable GHK-Cu (immunogenicity linked to aggregation and peptide-related impurities; limited data in humans).

Status: Information only. Not a food supplement; injectables are not approved. No product, no affiliate, no dose.

Dosing: THE FOCUX gives no dosing advice.

Further sources

1. Nat New Biol 1973 — tripeptide first described in human serum PMID 4349963
2. Int J Mol Sci 2018 — review of GHK-Cu gene-expression data PMID 29986520 · doi:10.3390/ijms19071987
3. CosIng (EU cosmetic ingredient database): COPPER TRIPEPTIDE-1, function: skin conditioning official text
4. US FDA — certain bulk drug substances for use in compounding that may present significant safety risks (GHK-Cu, injectable routes) official text

Info only, not medical advice.